AGP Executive Report
Last update: 9 hours agoCancer Care in Europe: The EU CHMP has issued a positive opinion for Merck’s KEYTRUDA (pembrolizumab) plus PADCEV (enfortumab vedotin) as perioperative treatment for cisplatin-ineligible resectable muscle-invasive bladder cancer, with a final European Commission decision expected in Q3 2026—relevant for patients in Liechtenstein, Iceland and Norway. Rare Disease Treatment: Pharming won EU marketing authorization for Joenja (leniolisib) for activated PI3K delta syndrome (APDS), the first approved option in the EU for patients aged 12+; first launch is expected in Germany in Q3 2026, with coverage including Liechtenstein. Sexual Health Alert: New ECDC data shows STI diagnoses across Europe hit record highs, with England flagged as likely the worst-hit by volume for syphilis, chlamydia and gonorrhoea—an urgent reminder for prevention and testing. Privacy & Consumer Tech: A review of Incogni highlights automated data-broker removal claims (hundreds of brokers, millions of requests), plus an audit reference—useful for digital wellbeing. Travel Health/Rules: UK guidance warns travellers not to bring meat or dairy from the EU, with potential fines up to £5,000—important for safe travel.
Note: AI summary from news headlines; neutral sources weighted more to help reduce bias in the result. Feedback is welcome. Please let us know if you have any comments or suggestions about the AGP Executive Report.
Perspectify News
![<![CDATA[EU CHMP Issues Positive Opinion for Perioperative Pembrolizumab/Enfortumab Vedotin in Cisplatin-Ineligible MIBC]]>](https://cdn.sanity.io/images/0vv8moc6/onclive/c32607911ff8c2b81ea841493078c23b4f97815c-1280x720.jpg)
